Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus Huaier granule in unresectable HCC
NCT07413354Phase 2Recruiting
- Sponsor
- Tongji Hospital
- Start
- Apr 2026
- Primary completion
- Mar 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, huaier granule in hepatocellular carcinoma (HCC), sponsored by Tongji Hospital. Started Apr 2026; status: recruiting.
02
Drugs
tislelizumabhuaier granule
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07413354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07413354.